In this double-blind, randomized, placebo-controlled, international study, researchers assessed the effectiveness and safety of pregabalin as adjunctive treatment for children (aged 4-16 years) with partial-onset seizures, termed focal onset seizures for this investigation. The criteria for selection included focal onset seizures and a stable regimen of 1 to 3 antiepileptic drugs. Pregabalin 2.5 mg/kg/d, 10 mg/kg/d or placebo were used in the study, with doses increased to 3.5 or 14 mg/kg/d for subjects weighing <30 kg. According to findings, pregabalin 10 mg/kg/d was effective in reducing the seizure frequency in children with focal onset seizures vs placebo, and both doses of pregabalin were generally safe and well tolerated. Common adverse events included somnolence, increased weight and increased appetite.
December 2, 2019
Three Anti-Seizure Drugs Equally Effective for Severe Form of Epilepsy
New findings published in the New England Journal of Medicine reveal that the three drugs, levetiracetam, fosphenytoin, and valproate, are equally safe and effective in treating patients with refractory status epilepticus.
November 26, 2019
Parent Reported Health Related Quality of Life (HRQoL) and Behavior in Young People with Epilepsy Before and Two Years After Epilepsy Surgery
The aim of this study was to compare parent-reported Health Related Quality of Life (HRQoL) and behavior of young people before (baseline) and two years after pediatric epilepsy surgery (follow-up).